WCG IPO Presentation Deck

Strong Track Record of Growth and Industry Transformation 14 Key Events 31% Revenue CAGR (2012-20) $53 ■ Revenue ($mm) Adjusted EBITDA ($mm)" $20 17% Organic Revenue CAGR (2012-20) 2012 2013 Transformed IRB Review 2014 35% Adj EBITDA CAGR (2012-20) 2015 Established New Standard for Predictive Site Selection 28% Organic Adj EBITDA CAGR (2012-20) (1) See appendix for a reconciliation of Adjusted EBITDA to the nearest GAAP measure. 2016 2017 Created New Paradigm for Patient Engagement $346 $146 2018 $413 $169 2019 Transforming Clinical Measurement Science $463 $218 2020 DNL wcg ~75% Visible Revenue (for the next twelve months) Predictable & Consistent Growth Unleashing Industry- Wide Clinical Trial Insights

View entire presentation